Study looks at drug resistance in BRAF-mutated gliomas

By | September 16, 2021
Looking to understand why some brain tumors with a specific mutation can start to reject drugs commonly used to treat them, CU Cancer Center member Jean Mulcahy Levy, MD, led researchers from institutions around the country -; including several from the University of Colorado School of Medicine -; to study samples of brain tumors before and after being treated with the drug.